These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 12029554)

  • 1. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
    Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
    Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.
    Murakami M; Miyamoto T; Iida T; Tsukada H; Watanabe M; Shida M; Maeda H; Nasu S; Yasuda S; Yasuda M; Ide M
    Int J Gynecol Cancer; 2006; 16 Suppl 1():99-107. PubMed ID: 16515575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
    García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
    Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
    Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
    Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
    Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
    Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
    Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
    Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
    Leblanc E; Gauthier H; Querleu D; Ferron G; Zerdoud S; Morice P; Uzan C; Lumbroso S; Lecuru F; Bats AS; Ghazzar N; Bannier M; Houvenaeghel G; Brenot-Rossi I; Narducci F
    Ann Surg Oncol; 2011 Aug; 18(8):2302-9. PubMed ID: 21347790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.